Clozapine and Haloperidol Differently Suppress the MK-801-Increased Glutamatergic and Serotonergic Transmission in the Medial Prefrontal Cortex of the Rat
The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Abstract
The administration of noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine and ketamine has been shown to increase the extracellular concentration of glutamate and serotonin (5-HT) in the medial prefrontal cortex (mPFC). In the present work, we used in vivo microdialysis to examine the effects of the more potent noncompetitive NMDA receptor antagonist, MK-801, on the efflux of glutamate and 5-HT in the mPFC, and whether the MK-801-induced changes in the cortical efflux of both transmitters could be blocked by clozapine and haloperidol given systemically or intra-mPFC. The systemic, but not the local administration of MK-801, induced an increased efflux of 5-HT and glutamate, which suggests that the NMDA receptors responsible for these effects are located outside the mPFC, possibly in GABAergic neurons that tonically inhibit glutamatergic inputs to the mPFC. The MK-801-induced increases of extracellular glutamate and 5-HT were dependent on nerve impulse and the activation of mPFC AMPA/kainate receptors as they were blocked by tetrodotoxin and NBQX, respectively. Clozapine and haloperidol blocked the MK-801-induced increase in glutamate, whereas only clozapine was able to block the increased efflux of 5-HT. The local effects of clozapine and haloperidol paralleled those observed after systemic administration, which emphasizes the relevance of the mPFC as a site of action of these antipsychotic drugs in offsetting the neurochemical effects of MK-801. The ability of clozapine to block excessive cortical 5-HT efflux elicited by MK-801 might be related to the superior efficacy of this drug in treating negative/cognitive symptoms of schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Paradoxically, MK-801 drives the increased release of glutamate in the mPFC, though the antipsychotic medications clozapine and haloperidol are both able to block MK-801-induced glutamate release in PFC of rats 169.”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [169]
In the citing paper
“Paradoxically, MK-801 drives the increased release of glutamate in the mPFC, though the antipsychotic medications clozapine and haloperidol are both able to block MK-801-induced glutamate release in PFC of rats 169.”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [169]
Citations
Cites
The Rat Brain in Stereotaxic Coordinates
(1982) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 51,963
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Cellular basis of working memory
Goldman-Rakic, P. S. (1995) · Neuron · doi:10.1016/0896-6273(95)90304-6 · Cited by 2,663
Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter
Giros, B., Jaber, M., Jones, S. R., Wightman, R. M., & Caron, M. G. (1996) · Nature · doi:10.1038/379606a0 · Cited by 2,476
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 4×
“Thus, all these findings suggest that NMDA receptor antagonists would attenuate the tonic activation of inhibitory (GABA) neurons (possibly, though not exclusively, in the hippocampus and/or the thalamus), which would result in a disinhibition of glutamatergic input to the mPFC (Olney and Farber, 1995; Moghaddam et al…”
BackgroundInfluentialGeyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484
Jentsch, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,314
Prefrontal cortex in the rat: Projections to subcortical autonomic, motor, and limbic centers
Gabbott, P. L. A., Warner, T. A., Jays, P. R. L., Salway, P., & Busby, S. J. (2005) · Journal of Comparative Neurology · doi:10.1002/cne.20738 · Cited by 1,227 · cited 1×
“Furthermore, only around 5% of projection neurons in the V layer of the mPFC project to the dorsal raphe nucleus, according to Gabbott et al. (2005).”
Background
Cited by
Items 101–183 of 183
Mora, S., Merchán, A., Vilchez, O., Aznar, S., Klein, A. B., Ultved, L., Campa, L., Sunol, C. E., Flores, P., & Moreno, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.09.004 · Cited by 31
“Neurochemical analyses The concentration of serotonin and glutamate in dialysate samples were determined by an HPLC system as described previously (Adell et al., 2002; López-Gil et al., 2007), with minor modifications.”
Woźniak, M., Gołembiowska, K., Noworyta, K., Acher, F., Cieślik, P., Kusek, M., Tokarski, K., Pilc, A., & Wierońska, J. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.06.025 · Cited by 25
Vines, L., Sotelo, D., Johnson, A., Dennis, E., Manza, P., Volkow, N. D., & Wang, G. (2022) · Intelligent Medicine · doi:10.1016/j.imed.2022.03.001 · Cited by 27
Roles of the monoaminergic system in the antidepressant effects of ketamine and its metabolites
Ago, Y., Yokoyama, R., Asano, S., & Hashimoto, H. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109313 · Cited by 26
Zhang, G., Krishnamoorthy, S., Ma, Z., Vukovich, N. P., Huang, X., & Tao, R. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.05.008 · Cited by 25
“We showed that, although (+) MK-801 alone caused an increase in 5-HT efflux (Lopez-Gil et al., 2007; also in this study), it attenuated 70 – 90% of the 5-HTP-evoked increase in 5-HT efflux.”
BackgroundScorza, M. C., Meikle, M. N., López‐Hill, X., Richeri, A., Lorenzo, D., & Artigas, F. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008432 · Cited by 30
Self-citationKutlu, M. D., Köse, S., & Akıllıoğlu, K. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114386 · Cited by 27
Sarasso, P., Billeci, M., Ronga, I., Raffone, F., Martiadis, V., & Petta, G. D. (2024) · Psychopathology · doi:10.1159/000539714 · Cited by 32
“According to this theory, ketamine blockade of NMDA receptors on GABAergic interneurons triggers a reduction of inhibitory control over pyramidal neurons [121 – 123].”
Electrophysiological effects of guanosine and MK-801 in a quinolinic acid-induced seizure model
Torres, F. V., Filho, M. D. S., Antunes, C., Kalinine, E., Antoniolli, E., Portela, L. V., Souza, D. O., & Tort, A. B. L. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.11.013 · Cited by 27
“, 1997; Moghaddam and Adams, 1998), which were postulated to involve disinhibition of glutamatergic principal cells promoted by less activation of GABAergic interneurons(Lopez-Gil et al., 2007; Moghaddam et al., 1997; Schmidt et al., 2009; Tort et al., 2004).”
BackgroundMoral‐Vico, J., Carretero, N. M., Pérez, E., Sunol, C. E., Lichtenstein, M. P., & Casañ-Pastor, N. (2013) · Electrochimica Acta · doi:10.1016/j.electacta.2013.08.041 · Cited by 25
Ferraro, L., Beggiato, S., Tomasini, M. C., Fuxé, K., Tanganelli, S., & Antonelli, T. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22686 · Cited by 27
“However, other authors have reported that systemically administered NMDA receptor antagonists increase cortical glutamate levels (Moghaddam et al., 1997; López-Gil et al., 2007).”
BackgroundThe preclinical discovery and development of paliperidone for the treatment of schizophrenia
Wesołowska, A., Jastrzębska‐Więsek, M., Cios, A., & Partyka, A. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1682994 · Cited by 22
“Utilizing this model of schizophrenia, paliperidone and risperidone showed effects similar to previously investigated clozapine and haloperidol [63,67,68].”
ResultRole of endocannabinoid and glutamatergic systems in DOI-induced head-twitch response in mice
Egashira, N., Shirakawa, A., Okuno, R., Mishima, K., Iwasaki, K., Oishi, R., & Fujiwara, M. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.003 · Cited by 23
Molecular imaging as a guide for the treatment of central nervous system disorders
Kim, E., Howes, O. D., & Kapur, S. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.3/ekim · Cited by 27
Nowak, K., Meyza, K., Nikolaev, E., Hunt, M., & Kasicki, S. (2012) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2012-1894 · Cited by 21
“Also, systemic application has been shown to increase the release of glutamate, dopamine, and serotonin in the mPFC (Mathé et al. 1999, López-Gil et al. 2007).”
BackgroundThe preclinical discovery and development of cariprazine for the treatment of schizophrenia
Wesołowska, A., Partyka, A., Jastrzębska‐Więsek, M., & Kołaczkowski, M. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1471057 · Cited by 25
de Bartolomeis, A., Iasevoli, F., Tomasetti, C., & Buonaguro, E. F. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8962-8 · Cited by 21
NMDA antagonist and antipsychotic actions in cortico-subcortical circuits
Kargieman, L., Santana, N., Mengod, G., Celada, P., & Artigas, F. (2008) · Neurotoxicity Research · doi:10.1007/bf03033805 · Cited by 22
Self-citationRebollo, B., Pérez‐Zabalza, M., Ruiz-Mejías, M., Perez-Mendez, L., & Sanchez-Vives, M. V. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.04.035 · Cited by 23
5-HT2A/C receptors mediate the antipsychotic-like effects of alstonine
Linck, V. M., Bessa, M. M., Herrmann, A. P., Iwu, M. M., Okunji, C. O., & Elisabetsky, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.08.022 · Cited by 23
Oh, H. K., Park, S. J., Bae, S. G., Kim, M. J., Jang, J. H., Ahn, Y. J., Woo, H., Kwon, G., & Ryu, J. H. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.01.032 · Cited by 22
Gobert, A., Rivet, J., Billiras, R., Parsons, F., & Millan, M. J. (2011) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2011.08.040 · Cited by 20
Castañé, A., Artigas, F., & Bortolozzi, A. A. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1205-9 · Cited by 20
“A local NMDA receptor blockade in mPFC does not seem to be fully responsible since local application of ketamine, PCP, b or MK-801 did not enhance the 5-HT output in rats or mice (Amargós-Bosch et al. 2006, López-Gil et al. 2007; this study).”
BackgroundInfluentialSelf-citationPotentiation of excitatory serotonergic responses by MK-801 in the medial prefrontal cortex
Labonté, B., Bambico, F. R., & Gobbi, G. (2009) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-009-0446-4 · Cited by 18
“In microdialysis studies, it was observed that low doses of NMDAR antagonists increase the extracellular concentration of glutamate in the mPFC (Moghaddam et al. 1997; Adams and Moghaddam 2001; Lorrain et al. 2003; Ceglia et al. 2004; Lopez-Gil et al. 2007).”
BackgroundResultInfluentialEffects of Hallucinogens on Neuronal Activity
Lladó-Pelfort, L., Celada, P., Riga, M. S., Troyano‐Rodriguez, E., Santana, N., & Artigas, F. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_473 · Cited by 19
“Moreover, systemic—but not local—administration of noncompetitive NMDA-R antagonists increased neurotransmitter release in PFC (Amargos-Bosch et al. 2006; Lopez-Gil et al. 2007), suggesting that NMDA-R blockade in other brain areas may also contribute to the increase in PFC activity.”
BackgroundSelf-citationCox, D., Gottschalk, M. G., Wesseling, H., Ernst, A., Cooper, J. D., & Bahn, S. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.06.012 · Cited by 17
Hervig, M. E.-S., Thomsen, M. S., Kalló, I., & Mikkelsen, J. D. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.07.028 · Cited by 19
“Several studies have shown that the PFC and MD are the predominant sites mediating the actions of non-competitive NMDAR antagonists, including changes in neurotransmission and behaviour (Amargós-Bosch et al. 2006; López-Gil et al. 2007; Kargieman et al. 2007; Zhang et al. 2009, 2012; Santana et al. 2011; Kiss et al. 2…”
A pharmacological MRI assessment of dizocilpine (MK-801) in the 3-nitroproprionic acid-lesioned rat
Roberts, T. J., Williams, S., & Modo, M. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.07.090 · Cited by 16
Influence of prenatal exposure to environmental pollutants on human cord blood levels of glutamate
Palou-Serra, A., Murcia, M., López-Espinosa, M.-J., Grimalt, J. O., Rodríguez-Farré, E., Ballester, F., & Sunol, C. E. (2013) · NeuroToxicology · doi:10.1016/j.neuro.2013.12.003 · Cited by 13
“Glutamate and aspartate cord plasma concentrations were determined by high performance liquid chromatography (HPLC)-fluorimetric analysis (Waters, Milford, MA; and Applied Biosystems, Foster City, CA) (Lopez-Gil et al., 2007; Reynolds et al., 2002).”
Casetta, C., Santosh, P., Bayley, R., Bisson, J. I., Byford, S., Dixon, C., Drake, R., Elvins, R., Emsley, R., Fung, N., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-023-05397-1 · Cited by 15
“…to most other antipsychotics, clozapine may be particularly effective in reducing expression of proinflammatory cytokines (e.g. IL-6), increasing expression of anti-inflammatory cytokines (e.g. IL-10) [32, 33], has greater antioxidant effects [34–36], and can reduce brain glutamate [37–39].”
BackgroundPsychotomimetic effects of PCP, LSD, and Ecstasy: pharmacological models of schizophrenia?
Catts, V. S., & Catts, S. V. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511789977.011 · Cited by 19
Takagi, S., Balu, D. T., & Coyle, J. T. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.12.034 · Cited by 12
“…the pharmacological NMDAR hypofunction models utilize sub-chronic NMDAR antagonist administration of 5–7 days (Daya et al., 2014; Eyjolfsson et al., 2006; Hawken et al., 2013), or even shorter (Khella et al., 2014; Lopez-Gil et al., 2007; Manahan-Vaughan et al., 2008; Park et al., 2014) durations.”
Daniels, S., Mansari, M. E., Hamoudeh, R. A., & Blier, P. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1276309 · Cited by 12
Park, S. J., Jeon, S. J., Peña, I. D., Lee, H. E., Kim, D. H., Kim, J., Lee, Y. W., Jung, J. M., Shin, B. Y., Lee, S., et al. (2013) · Phytotherapy Research · doi:10.1002/ptr.4929 · Cited by 10
“In previous studies, the systemic administration of haloperidol at a high dose (0.5–1mg/kg) but not at a low dose (0.01–0.1mg/kg) (Lopez-Gil et al., 2007) blocked theMK801-induced increase in glutamate in the medial prefrontal cortex.”
BackgroundInfluentialIsherwood, S. N., Robbins, T. W., Dalley, J. W., & Pekcec, A. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14290 · Cited by 11
“Thus, the population of NMDA receptors responsible for the effects of MK801 on glutamate release appear to be located outside the PFC, possibly on GABA-ergic neurons tonically involved in inhibiting glutamatergic input to the PFC (Lopez-Gil et al. 2007).”
BackgroundBergstrom, H. C., Darvesh, A. S., & Berger, S. P. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00292 · Cited by 10
“Clozapine and haloperidol were both found to attenuate MK-801-induced glutamate release in the mPFC (Lopez-Gil et al., 2007).”
BackgroundZou, Y., Zhang, H., Chen, X., Ji, W., Mao, L., & Lei, H. C. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104503 · Cited by 10
Cassetta, B. D., Menon, M., Carrion, P. B., Pearce, H. L., DeGraaf, A., Leonova, O., White, R. F., Stowe, R., Honer, W. G., Woodward, T. S., et al. (2019) · The Clinical Neuropsychologist · doi:10.1080/13854046.2019.1694072 · Cited by 9
Jiang, X., Liang, P., Wang, K., Jia, J., & Wang, X. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108881 · Cited by 10
Aluisio, L. E., Fraser, I. C., Berdyyeva, T. K., Tryputsen, V., Shireman, B. T., Shoblock, J. R., Lovenberg, T. W., Dugovic, C., & Bonaventure, P. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00107 · Cited by 9
“Timothy Lovenberg participated in research design.”
BackgroundWang, Y., Liu, J., Wang, J., Shang, J., & Gao, Y.-L. (2023) · Journal of Computational Biology · doi:10.1089/cmb.2023.0078 · Cited by 8
LaCrosse, A., May, C. E., Griffin, W. C., & Olive, M. F. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.06.016 · Cited by 9
Ossowska, K., Kosmowska, B., & Wardas, J. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00093-3 · Cited by 8
Martin, C. B. P., Gassmann, M., Chevarin, C., Hamon, M., Rudolph, U., Bettler, B., Lanfumey, L., & Mongeau, R. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12929 · Cited by 9
Xanthouhumol relieves stress-induced depressive-like behaviors through the Sirt1/NF-κB/NLRP3 pathway
Lin, G., Zhang, Y., Qin, J., He, Y., Fan, L., Tan, Q., & Xie, P. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06819-6 · Cited by 10
“Further, reductions in critical synaptic proteins and dysregulation of neurotransmitters, particularly glutamate and serotonin, intensify synaptic dysfunction in the mPFC (López-Gil et al. 2007).”
Electrophysiological phenotypes of suicidality predict prolonged response to oral ketamine treatment
Can, A., Schwenn, P., Isbel, B., Beaudequin, D. A., Bouças, A. P., Dutton, M., Jones, M., Gallay, C. C., Forsyth, G., Bennett, M. R., et al. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110701 · Cited by 8
Gliaudelytė, L., Rushton, S., Palmini, R. B., Thomas, A. J., & Morris, C. M. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03298-3 · Cited by 5
¿Antidepresivos glutamatérgicos? Las sorprendentes propiedades antidepresivas de la quetamina
Artigas, F. (2011) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2011.07.002 · Cited by 7
Self-citationDaniels, S., Mansari, M. E., & Blier, P. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01958-4 · Cited by 7
“The increase in 5-HT release in the mPFC produced by the NMDA antagonist MK-801 is also blocked by NBQX [47, 48].”
BackgroundHickman, L., Sowden-Carvalho, S., Fraser, D. S., Schuster, B. A., Rybicki, A. J., Galea, J. M., & Cook, J. L. (2024) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.115213 · Cited by 10
Wang, C.-M., Lin, Z.-H., Lin, Z.-Q., Yao, Q.-Y., & Zhang, Y.-F. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118812099 · Cited by 5
Animal Models and Hallucinogenic Drugs
Kozlenkov, A., & González‐Maeso, J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4121-2_14 · Cited by 6
Adraoui, F. W., Violas, M., Viardot, G., Hettak, K., Tugler, S., Delpy, E., Maurin, A., L’Hostis, P., Rochelle, C. D. L., & Carvalho, K. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111555 · Cited by 4
La kétamine : un neuropsychotrope au mécanisme d’action innovant
Guilloux, J., Nguyen, T. M. L., & Gardier, A. M. (2023) · Biologie Aujourd hui · doi:10.1051/jbio/2023026 · Cited by 5
Straathof, M., Blezer, E. L. A., Smeele, C. E., Heijningen, C. L. V., van der Toorn, A., Buitelaar, J. K., Glennon, J. C., Otte, W. M., Dijkhuizen, R. M., Buitelaar, J. K., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06139-z · Cited by 4
“Micro-dialysis studies have suggested that NMDA-receptor antagonists can activate prefrontal areas by increasing the glutamatergic tone (Moghaddam et al. 1997; López-Gil et al. 2007), which can activate other glutamatergic receptors.”
BackgroundAnti-migraine activity of freeze-dried latex obtained from Calotropis gigantea Linn
Bhatia, S., Al‐Harrasi, A., Kumar, A., Behl, T., Sehgal, A., Singh, S., Sharma, N., Anwer, M. K., Kaushik, D. K., Mittal, V., et al. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-17810-x · Cited by 5
Gamma oscillations in the mouse primary visual cortex as an endophenotype of schizophrenia
Welle, C. G. (2010) · ScholarlyCommons (University of Pennsylvania) · Cited by 5
MK-801 reduces sensitivity to Müller-Lyer's illusion in capuchin monkeys
Jacobsen, M. E., Barros, M., & Maior, R. S. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.08.043 · Cited by 4
Morris, B. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111628 · Cited by 2
Feng, Z., Hu, Z., Li, L., Yu, M., Zhang, Y., Peng, J., Xu, X., Wu, J., Hu, Y., & Xu, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1298061 · Cited by 2
What value do NMDA receptor antagonist models of schizophrenia have for novel drug discovery?
Adell, A. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2562017 · Cited by 2
Self-citationMonitoring Neurotransmitter Amino Acids by Microdialysis: Pharmacodynamic Applications
Parrot, S., Renaud, B., Zimmer, L., & Denoroy, L. (2011) · Wiley eBooks · doi:10.1002/9781118011294.ch5 · Cited by 4
Neuropharmacological targets for schizophrenia treatment: An update
de Lima, C. A. C., Barbosa, M. E. O., de Souza-Júnior, F. J. C., Farias, S. V., Fontes-Júnior, E. A., & Maia, C. D. S. F. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111580 · Cited by 1
Sun, J., Zelaya, F. O., Sendt, K.-V., McQueen, G., Gillespie, A. L., Lally, J., O’Daly, O., Lythgoe, D. J., Howes, O. D., Barker, G. J., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251409141 · Cited by 1
“…2007; Malhotra et al., 1997), suppression of hyperglutamatergic activity via activation of presynaptic group metabotropic glutamate receptors (e.g. III-mGluR) (Fukuyama et al., 2019), and attenuating MK-801-induced increases in glutamate release in the frontal cortex (López-Gil et al., 2007).”
Li, Q., Chan, W. M., Rudd, J. A., Wang, C. M., Lam, P. Y. H., Wai, M. S. M., Wood, D. M., Dargan, P. I., & Yew, D. T. W. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415816-0.00012-2 · Cited by 2
Dybowski, F. P., Scott, D. S., & Tamminga, C. A. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02077-4 · Cited by 1
Umino, M., Shiraku, H., Umino, A., Kiuchi, Y., & Nishikawa, T. (2025) · ChemBioChem · doi:10.1002/cbic.202500209 · Cited by 1
Inhibition of Glycine Transporter-1 Improves the Functional Outcome of Schizophrenia
Hui, C., & Tsai, G. E. (2010) · Springer eBooks · doi:10.1007/978-90-481-8553-5_19 · Cited by 1
Ohba, T., Fujimori, H., Nakamura, S., Hayashi, Y., Kono, H., Shimazawa, M., & Hara, H. (2021) · BPB Reports · doi:10.1248/bpbreports.4.5_155 · Cited by 1
Receptores Monoaminérgicos en Corteza Prefrontal: Mecanismo de Acción de Fármacos Antipsicóticos
Ramos, N. S. (2007) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · Cited by 1
Neural mechanisms of MK-801 induced sensitisation
Lefevre, E. M. (2016) · The University of Queensland · doi:10.14264/uql.2016.911 · Cited by 1
NEUROPEPTIDE Y (NPY) AND GLUTAMATE TRANSPORTER (GLAST) IN BEHAVIORAL MODELS OF PSYCHIATRIC DISORDERS
Karlsson, R. (2008) · Figshare · Cited by 1
Gil, J. L. (2009) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
d-Serine Signaling and Schizophrenia
Nishikawa, T. (2016) · Springer eBooks · doi:10.1007/978-4-431-56077-7_6
Glutamatergic antidepressants? The intriguing antidepressant properties of ketamine
Artigas, F. (2011) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2011.07.002 · Cited by 1
Self-citationAbad-Perez, P., Payá, F. J. M., Martínez-Otero, L., Borrell, V., Redondo, R. L., & Brotons‐Mas, J. R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.22.461383
“Additionally, animal models of schizophrenia based on NMDAr hypofunction successfully mimic the positive, negative, and cognitive symptoms as well as structural brain changes observed in schizophrenic patients (Abekawa et al., 2007; Eyjolfsson et al., 2006; Jodo, 2013; López-Gil et al., 2007; Murueta-Goyena Larrañaga…”
BackgroundConnecting the dots: Structural and functional connections in healthy and diseased brain
Straathof, M. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/877
A KETAMIN HATÁSA A TERÁPIAREZISZTENS MAJOR DEPRESSZIÓRA
SZTE BTK, P. I., & Peszeki, N. (2017) · Psychologia Hungarica Caroliensis · doi:10.12663/psyhung.5.2017.1.3
Tuplin, E. W. N. (2014) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2014-10451
Castañé, A., & Adell, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-70474-6_8
Self-citationGlutamatergic dysfunction is associated with phenotypes of VGF-overexpressing mice
Mizoguchi, T., Fujimori, H., Ohba, T., Shimazawa, M., Nakamura, S., Shinohara, M., & Hara, H. (2022) · Experimental Brain Research · doi:10.1007/s00221-022-06384-w
Role of prefrontal cortex in pharmacological models of schizophrenia and antipsychotic action
Celada, P., Adell, A., López-Gil, X., Kargieman, L., Santana, N., Bortolozzi, A. A., Castañé, A., & Artigas, F. (2009) · DIGITAL.CSIC (Spanish National Research Council (CSIC)) · Cited by 1
Self-citation
Metadata
- Authors
- López-Gil, X., Babot, Z., Amargós-Bosch, M., Suñol, C., Artigas, F., & Adell, A.
- Affiliations
- Consejo Superior de Investigaciones Científicas (ES)
- Corresponding author
- Adell, Albert
- Venue
- Neuropsychopharmacology
- Published
- 2007-03-14
- Volume
- 32
- Issue
- 10
- Pages
- 2087-2097
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2084299214
- Cited by
- 183
- References
- 89
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 6 · 2023: 4 · 2022: 7 · 2021: 9 · 2020: 8 · 2019: 7 · 2018: 10 · 2017: 7 · 2016: 13 · 2015: 10 · 2014: 16 · 2013: 13 · 2012: 7
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Funders
- Generalitat de Catalunya (SGR-2005)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- clozapine, haloperidol, MK-801, NMDA receptor antagonists, medial prefrontal cortex, glutamate efflux, serotonin efflux, non-NMDA receptors, antipsychotic drugs, negative symptoms of schizophrenia, cognitive symptoms, tetrodotoxin, NBQX, local drug administration
- MeSH terms
- Animals, Clozapine, gamma-Aminobutyric Acid, Haloperidol, Male, Synaptic Transmission, Schizophrenia, Serotonin, Antipsychotic Agents, Dizocilpine Maleate, Rats, Wistar, Prefrontal Cortex, Microdialysis, Receptors, AMPA, Excitatory Amino Acid Antagonists, Glutamic Acid, Extracellular Fluid, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.